[P68] ポスターセッション 68　臨床試験推進プログラム

[P68-9] SERENA-6: a Phase III study of AZD9833 plus CDK4/6i in HR+/HER2- mBC with detectable ESR1m before disease progression

^○高橋 將人¹, Bidard Francois-Clement², Kalinsky Kevin³, Cristofanilli Massimo⁴, Bianchini Giampaolo⁵, Chia Stephen⁶, Janni Wolfgang⁷, Ma Cynthia⁸, Mayer Erica⁹, Park Yeon Hee¹⁰, Fox Steven¹¹, Liu Xiaochun¹², Walding Andrew¹¹, Huang-Bartlett Cynthia¹², Turner Nicholas¹³ (1.国立病院機構北海道がんセンター 乳腺外科, 2.Institut Curie, Paris, France, 3.Emory University, Atlanta, GA, 4.Northwestern University Feinberg School of Medicine, Chicago, IL, 5.IRCCS Ospedale San Raffaele, Milan, Italy, 6.British Columbia Cancer Agency, Vancouver, BC, Canada, 7.University Hospital Ulm, Ulm, Germany, 8.Washington University School of Medicine, St Louis, MO, 9.Dana-Farber Cancer Institute, Boston, MA, 10.Sungkyunkwan University School of Medicine, Seoul, Korea, 11.AstraZeneca, Cambridge, United Kingdom, 12.AstraZeneca, Gaithersburg, MD, 13.Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom)